
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is in a strong position with their divestment of non-Rolvedon assets to Cosette for an upfront payment of $35M plus potential earnouts related to certain product milestones at a low multiple of <1x historical one-year sales. This allows the company to focus on their core products in the oncology market, while also having the opportunity for additional revenue through the CVR attached to the Sprix-related milestones. The 20-day "window-shop" period also provides potential for a superior bid, but given the limited potential for other bidders, we do not anticipate this leading to a protracted bidding war.
Bears say
Assertio Hldgs is facing challenges with its products in the competitive oncology market and is at risk of not achieving its potential potential. Additionally, the company's decision to sell non-Rolvedon assets to the privately-held Cosette Pharmaceuticals could impact its future growth potential. The recent reverse stock split and CVR non-tradeable component also add uncertainty to the company's future performance, leading me to have a negative outlook on its stock.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares